Setting New Standards in Prostate Cancer Management With EMBARK With Stephen Freedland, MD

Read the full interview on Oncology Data Advisor: https://oncdata.com/embark-esmo-stephen-freedland At ESMO, the EMBARK trial delivered practice-changing overall survival data for men with high-risk biochemically recurrent (BCR) prostate cancer after surgery or radiation. In this interview, Stephen Freedland, MD, reviews how EMBARK was designed, the newest OS results, and what they mean for everyday practice. Learn how androgen deprivation therapy (ADT) plus enzalutamide achieved an unprecedented greater than 40% relative reduction in risk of death in high-risk BCR disease; when to use combination therapy versus enzalutamide monotherapy; and how PSA doubling time should guide treatment selection. Dr. Freedland also shares practical tips for managing toxicities such as fatigue, falls, hot flashes, seizures, and gynecomastia, while preserving quality of life. He explains how treatment suspension after response was incorporated into the trial and how ongoing analyses may further refine on/off strategies over time. #ProstateCancer #EMBARKTrial #Enzalutamide #BiochemicalRecurrence #ESMO2025 #AndrogenDeprivationTherapy #ADT #PSADoublingTime #UrologicOncology #PrecisionOncology #HormoneTherapy #ClinicalTrials #OncologyEducation #PatientOutcomes